Obesity and its fatal sequelae are among the most prevalent and challenging morbidities confronting the medical profession in the 21^^ century. Obesity leads to insulin resistance, hyperglycemia, and dyslipidemia. To lower blood glucose, the pancreas produces excess insulin which stimulates the liver to convert excess glucose to FAs and TGs. The increased FAs produce two potentially fatal sequelae: 1) elevated plasma lipids and atherosclerosis, leading to death from myocardial infarction or stroke; and 2) fatty liver, which can lead to death from cirrhosis and liver failure. The burden of these FA-related complications is enormous. More than half of the deaths in obese type 2 diabetics are attributable to cardiovascular disease (1). Moreover, more than one-third of the US population accumulates excess TGs in liver (2) a condition known as non-alcoholic fatty liver disease (NAFLD), which accounts for 10% of the liver transplants in the US (3). If we are to combat the deadly consequences of excess FA synthesis, we must understand the regulatory factors that trigger this response. Our Program Project Grant made an important start with two discoveries: 1) that SREBP-lc is the key protein mediating insulin stimulation of FA synthesis in the liver;and 2) that an SREBP-lc target gene, MIG12, encodes a protein that markedly stimulates the activity of acetyl-CoA carboxylase (ACC), the first committed enzyme in FA synthesis. If we successfully complete the studies outlined in Research Project 3, we will have laid the basis for a new strategy to prevent the excess synthesis of FAs, and ameliorate the fatal consequences of obesity and diabetes.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL020948-38
Application #
8686024
Study Section
Heart, Lung, and Blood Program Project Review Committee (HLBP)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
38
Fiscal Year
2014
Total Cost
Indirect Cost
City
Dallas
State
TX
Country
United States
Zip Code
75390
Gusarova, Viktoria; Banfi, Serena; Alexa-Braun, Corey A et al. (2017) ANGPTL8 Blockade With a Monoclonal Antibody Promotes Triglyceride Clearance, Energy Expenditure, and Weight Loss in Mice. Endocrinology 158:1252-1259
Zhang, Yue; Udayakumar, Durga; Cai, Ling et al. (2017) Addressing metabolic heterogeneity in clear cell renal cell carcinoma with quantitative Dixon MRI. JCI Insight 2:
Rong, Shunxing; Cortés, Víctor A; Rashid, Shirya et al. (2017) Expression of SREBP-1c Requires SREBP-2-mediated Generation of a Sterol Ligand for LXR in Livers of Mice. Elife 6:
Rong, Shunxing; McDonald, Jeffrey G; Engelking, Luke J (2017) Cholesterol auxotrophy and intolerance to ezetimibe in mice with SREBP-2 deficiency in the intestine. J Lipid Res 58:1988-1998
Chakrabarti, Rima S; Ingham, Sally A; Kozlitina, Julia et al. (2017) Variability of cholesterol accessibility in human red blood cells measured using a bacterial cholesterol-binding toxin. Elife 6:
Infante, Rodney Elwood; Radhakrishnan, Arun (2017) Continuous transport of a small fraction of plasma membrane cholesterol to endoplasmic reticulum regulates total cellular cholesterol. Elife 6:
Kim, Chai-Wan; Addy, Carol; Kusunoki, Jun et al. (2017) Acetyl CoA Carboxylase Inhibition Reduces Hepatic Steatosis but Elevates Plasma Triglycerides in Mice and Humans: A Bedside to Bench Investigation. Cell Metab 26:394-406.e6
Stender, Stefan; Kozlitina, Julia; Nordestgaard, Børge G et al. (2017) Adiposity amplifies the genetic risk of fatty liver disease conferred by multiple loci. Nat Genet 49:842-847
Fitzgerald, Kevin; White, Suellen; Borodovsky, Anna et al. (2017) A Highly Durable RNAi Therapeutic Inhibitor of PCSK9. N Engl J Med 376:41-51
Zhang, Yuanyuan; Zhang, Yajie; Yu, Yonghao (2017) Global Phosphoproteomic Analysis of Insulin/Akt/mTORC1/S6K Signaling in Rat Hepatocytes. J Proteome Res 16:2825-2835

Showing the most recent 10 out of 753 publications